Saiid Zarrabian Healthcare News

This is selected healthcare news for Saiid Zarrabian, which is filed under People. There are 56 news items for this page. A press release filter page is also available for Saiid Zarrabian.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
10/11/2021 Kintara Therapeutics to Present at the LD Micro Main Event Conference
... Kintara Therapeutics, Inc . (Nasdaq: KTRA ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Saiid Zarrabian , will present a corporate overview at the 14 th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset ...
PR Newswire
8/17/2021 Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
... clinical trial centers worldwide. "The entire Kintara team remains enthused by the pace at which our treatment arm is being activated in the study," commented Saiid Zarrabian , Kintara's Chief Executive Officer. "With 26 sites already active, including the recent addition of prestigious centers such as the Dana Farber Cancer Institute ...
PR Newswire
8/12/2021 Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021
SAN DIEGO Kintara Therapeutics, Inc . (Nasdaq: KTRA ), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that its Chief Executive Officer, Saiid Zarrabian , will present at the Investor Summit Conference being held August 17 ‚Ai 18, 2021. Mr ...
PR Newswire
8/4/2021 Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021
SAN DIEGO Kintara Therapeutics, Inc . (Nasdaq: KTRA ), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that Saiid Zarrabian , Chief Executive Officer, will participate at the BTIG Virtual Biotechnology Conference on August 9, 2021 . Mr. Zarrabian will deliver ...
PR Newswire
5/4/2021 Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors
... are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," commented Saiid Zarrabian , Kintara's President and Chief Executive Officer. "Tamara's insights and perspectives will be a valuable addition to the Board and the entire Company as ...
PR Newswire
10/21/2020 Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083’s Participation in the GBM AGILE Registrational Study
... facilitation of the final clinical stages and the regulatory process for our novel therapeutic candidate while enabling us to maximize financial and operational resources," commented Saiid Zarrabian , Kintara's Chief Executive Officer. "The GCAR opportunity is a more robust, efficient, and cost-effective clinical trial solution than had we embarked on ...
PR Newswire
9/21/2020 Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates
... important periods in the Company's history, as it set the stage for the recently consummated acquisition of Adgero which was truly a transformational milestone," commented Saiid Zarrabian , President and Chief Executive Officer of Kintara. "Moving forward, we believe we are now well positioned to execute our growth strategy as we ...
gurufocus.com
8/26/2020 Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD Micro 500 Virtual Conference on September 3rd, 2020
SAN DIEGO Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA ) announced today that Saiid Zarrabian , Chief Executive Officer of Kintara, will give a virtual corporate presentation at the LD Micro 500 taking place online on Thursday, September 3, 2020 at 4:00 PM ET followed by ...
PR Newswire
8/26/2020 Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD Micro 500 Virtual Conference on September 3rd, 2020
SAN DIEGO , Aug. 26, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that Saiid Zarrabian , Chief Executive Officer of Kintara, will give a virtual corporate presentation at the LD Micro 500 taking place online on Thursday, September 3, 2020 at 4:00 ...
BioSpace
8/20/2020 Kintara Therapeutics (Formerly DelMar Pharmaceuticals) Announces Completion of Merger with Adgero Biopharmaceuticals and Closing of $19.6 Million Private Placement Priced At-The-Market
... in year one to 25% in year four. The board of directors of Kintara is now comprised of Robert Hoffman , Laura Johnson , Rob Toth and Saiid Zarrabian , who are current directors of the Company, and John Liatos and Keith Murphy from Adgero. The shares of Preferred Stock described above were ...
PR Newswire
7/17/2020 DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals
... The call will be held Thursday, July 23, 2020 at 4:30PM ET . Conference Call Dial-In and Webcast Details The call will include remarks by Saiid Zarrabian , president and CEO, Scott Praill , chief financial officer and Greg Johnson , senior VP of Operations. A slide presentation will accompany the call and ...
PR Newswire
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
... Tumor Society and the National Foundation for Cancer Research as these organizations are two of the leading advocacy and funding partners for GBM AGILE," commented Saiid Zarrabian , Chief Executive Officer of DelMar Pharmaceuticals. "This funding is an important milestone as it enables us to accelerate VAL-083's participation in ...
Benzinga
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
... Tumor Society and the National Foundation for Cancer Research as these organizations are two of the leading advocacy and funding partners for GBM AGILE," commented Saiid Zarrabian , Chief Executive Officer of DelMar Pharmaceuticals. "This funding is an important milestone as it enables us to accelerate VAL-083's participation in ...
gurufocus.com
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
... Tumor Society and the National Foundation for Cancer Research as these organizations are two of the leading advocacy and funding partners for GBM AGILE,” commented Saiid Zarrabian, Chief Executive Officer of DelMar Pharmaceuticals. “This funding is an important milestone as it enables us to accelerate VAL-083's participation in ...
nfcr.org
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research
... Tumor Society and the National Foundation for Cancer Research as these organizations are two of the leading advocacy and funding partners for GBM AGILE," commented Saiid Zarrabian , Chief Executive Officer of DelMar Pharmaceuticals. "This funding is an important milestone as it enables us to accelerate VAL-083's participation in ...
PR Newswire
6/10/2020 DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
... increased shareholder value by bringing together DelMar's oncology therapeutic candidate, VAL-083, and Adgero's REM-001 photodynamic therapy with a lead indication in CMBC," commented Saiid Zarrabian , President and Chief Executive Officer of DelMar. "This acquisition is the result of an extensive search for a suitable oncology therapy and provides ...
BioSpace
6/10/2020 DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
... increased shareholder value by bringing together DelMar's oncology therapeutic candidate, VAL-083, and Adgero's REM-001 photodynamic therapy with a lead indication in CMBC," commented Saiid Zarrabian , President and Chief Executive Officer of DelMar. "This acquisition is the result of an extensive search for a suitable oncology therapy and provides ...
gurufocus.com
6/4/2020 Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
... as strong regulatory endorsement can measurably accelerate our efforts to bring VAL-083 to market for GBM patients who have significant unmet medical needs," commented Saiid Zarrabian , Chief Executive Officer of DelMar Pharmaceuticals. "With 24 clinical sites currently enrolling patients and with additional sites in the US, Canada , Europe and ...
BioSpace
6/4/2020 Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
... as strong regulatory endorsement can measurably accelerate our efforts to bring VAL-083 to market for GBM patients who have significant unmet medical needs," commented Saiid Zarrabian , Chief Executive Officer of DelMar Pharmaceuticals. "With 24 clinical sites currently enrolling patients and with additional sites in the US, Canada , Europe and ...
gurufocus.com
6/4/2020 Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme
... as strong regulatory endorsement can measurably accelerate our efforts to bring VAL-083 to market for GBM patients who have significant unmet medical needs," commented Saiid Zarrabian , Chief Executive Officer of DelMar Pharmaceuticals. "With 24 clinical sites currently enrolling patients and with additional sites in the US, Canada , Europe and ...
PR Newswire
5/13/2020 DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates
... 2020 and provided a corporate update. "We continue to be pleased with the rapid enrollment pace in both of our Phase 2 GBM trials," stated Saiid Zarrabian , CEO of DelMar Pharmaceuticals. "While we cannot predict the future impact of COVID-19 on our studies at MD Anderson Cancer Center in ...
PR Newswire
3/4/2020 DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors
... to see both that arm, and the recurrent arm continue to enroll patients steadily. We will continue to provide updates as they become available," commented Saiid Zarrabian , DelMar's Chief Executive Officer. "In the meantime, having completed enrollment of our first-line study, we continue to anticipate an initial data readout ...
PR Newswire
3/4/2020 DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors
... to see both that arm, and the recurrent arm continue to enroll patients steadily. We will continue to provide updates as they become available," commented Saiid Zarrabian , DelMar's Chief Executive Officer. "In the meantime, having completed enrollment of our first-line study, we continue to anticipate an initial data readout ...
Yahoo News
2/19/2020 DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors
... first-line GBM patients earlier than anticipated. We are optimistic that we will receive the initial data readout before the end of August 2020 ," commented Saiid Zarrabian , DelMar's Chief Executive Officer. "In the meantime, we continue to rapidly advance our other Phase 2 program in the adjuvant and recurrent settings ...
PR Newswire
2/13/2020 DelMar Pharmaceuticals Announces Fiscal Second Quarter 2020 Financial Results and Recent Corporate Updates
... our upcoming update of clinical data at the American Association for Cancer Research Annual Meeting being held in San Diego April 24 to 29 ," commented Saiid Zarrabian , DelMar's President and Chief Executive Officer. "Following a productive quarter, we continue to believe that our cash position will provide the runway to ...
PR Newswire